Immuno-Oncology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
60
NCT04282044
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 8, 2021
Completion: Oct 31, 2026
Loading map...